Potential-resolved electrochemiluminescence (PRECL)-based strategies utilizing novel nanoluminophores have become a research hotspot in analytical sciences in virtue of the superior versatility, specificity, and sensitivity they offer to bioassays. In this work, novel PRECL nanoluminophore graphitic carbon nitrides (g-C 3 N 4 ) functionalized by N-(aminobutyl)-N-(ethylisoluminol) (ABEI) (g-C 3 N 4 /ABEI) were developed, exhibiting two potential-resolved ECL emissions in the presence of H 2 O 2 /K 2 S 2 O 8 as coreactants with the peak potentials at +1.2 and −1.6 V, respectively. It was found that Hg 2+ could simultaneously decrease the ABEI electrochemiluminescence (ECL) intensity while increasing the intensity of g-C 3 N 4 on the contrary. Using Hg 2+ as the ECL signal moderator based on specific interactions between Hg 2+ and thymine–thymine pairs, conjoined with the synthesized g-C 3 N 4 /ABEI/Hg 2+ nanohybrids with outstanding PRECL properties as the sensing interface, a label-free and all-in-one ratiometric ECL bioassay combined with a rolling circle amplification (RCA) strategy was designed for the detection of miR-133a as a biomarker in early diagnosis of acute myocardial infarction (AMI). The proposed bioassay provided a quantitative readout proportional to the target miR-133a concentrations in the range from 0.1 fM to 1.0 pM with a detection limit of 48.0 aM. Owing to its inherent merits for an effective amplification of the ECL signals ratio and a simple one-step assembly procedure, the proposed bioassay demonstrated excellent analytical performance with remarkable sensitivity, specificity, and low measurement deviations, manifesting its potential application in early AMI diagnosis.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: